Cite
PCN208 COST-EFFECTIVENESS OF NIVOLUMAB FOR THE ADJUVANT TREATMENT OF PATIENTS WITH MELANOMA WITH INVOLVEMENT OF LYMPH NODES OR METASTATIC DISEASE WHO HAVE UNDERGONE COMPLETE RESECTION: AN ANALYSIS FROM A SWISS HEALTHCARE SYSTEM PERSPECTIVE.
MLA
Oniangue-Ndza, C., et al. “Pcn208 Cost-Effectiveness of Nivolumab for the Adjuvant Treatment of Patients with Melanoma with Involvement of Lymph Nodes or Metastatic Disease Who Have Undergone Complete Resection: An Analysis from a Swiss Healthcare System Perspective.” Value in Health, vol. 22, Nov. 2019, p. S476. EBSCOhost, https://doi.org/10.1016/j.jval.2019.09.404.
APA
Oniangue-Ndza, C., Strittmatter, G., Orsini, I., Teitsson, S., Augusto, M., & Amadi, A. (2019). Pcn208 Cost-Effectiveness of Nivolumab for the Adjuvant Treatment of Patients with Melanoma with Involvement of Lymph Nodes or Metastatic Disease Who Have Undergone Complete Resection: An Analysis from a Swiss Healthcare System Perspective. Value in Health, 22, S476. https://doi.org/10.1016/j.jval.2019.09.404
Chicago
Oniangue-Ndza, C., G. Strittmatter, I. Orsini, S. Teitsson, M. Augusto, and A. Amadi. 2019. “Pcn208 Cost-Effectiveness of Nivolumab for the Adjuvant Treatment of Patients with Melanoma with Involvement of Lymph Nodes or Metastatic Disease Who Have Undergone Complete Resection: An Analysis from a Swiss Healthcare System Perspective.” Value in Health 22 (November): S476. doi:10.1016/j.jval.2019.09.404.